Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.2900 (-6.95%) ($6.2800 - $6.7900) on Thu. Aug. 22, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.87% (three month average) | RSI | 39 | Latest Price | $6.2900(-6.95%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -0.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.935% in a week (0% probabilities). VIXM(-39%) VXX(-37%) TLT(-9%) IFRA(-7%) UUP(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.935% (StdDev 3.87%) | Hourly BBV | 0 () | Intraday Trend | -6.5% | | | |
|
1 - 5 Day Possible Target | $-3.12(-149.6%) | Resistance Level | $6.95 | 5 Day Moving Average | $6.68(-5.84%) | 10 Day Moving Average | $6.82(-7.77%) | 20 Day Moving Average | $6.95(-9.5%) | To recent high | -30% | To recent low | 0.3% | Market Cap | $797m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |